Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Stephen A. Cannistra, M.D.

Title
Institution
Department
Address
Phone
Fax

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R01CA060670 (CANNISTRA, STEPHEN A) Aug 1, 1993 - May 31, 1998
    NIH/NCI
    ADHESION PROTEIN AND OVARIAN CANCER IMPLANTATION
    Role: Principal Investigator
  2. F32CA007765 (CANNISTRA, STEPHEN A) Jul 1, 1986
    NIH/NCI
    ROLE OF IA ANTIGENS IN REGULATION OF HUMAN MYELOPOIESIS
    Role: Principal Investigator
  3. M01RR001032 (SUKHATME, VIKAS P) Dec 1, 1977 - Nov 30, 2004
    NIH/NCRR
    General Clinical Research Center
    Role: Co-Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Cannistra SA, Haffty BG, Ballman K. Challenges Faced by Medical Journals During the COVID-19 Pandemic. J Clin Oncol. 2020 07 01; 38(19):2206-2207. PMID: 32267782.
    Citations:    
  2. Cannistra SA. Journal of Clinical Oncology's Data Sharing Policy for Clinical Trials. J Clin Oncol. 2019 12 10; 37(35):3333-3334. PMID: 31805249.
    Citations:    
  3. Liu JF, Herold C, Gray KP, Penson RT, Horowitz N, Konstantinopoulos PA, Castro CM, Hill SJ, Curtis J, Luo W, Matulonis UA, Cannistra SA, Dizon DS. Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial. JAMA Oncol. 2019 Oct 10. PMID: 31600397.
    Citations:    
  4. DeLeonardis K, Hogan L, Cannistra SA, Rangachari D, Tung N. When Should Tumor Genomic Profiling Prompt Consideration of Germline Testing? J Oncol Pract. 2019 09; 15(9):465-473. PMID: 31509718.
    Citations:    
  5. Konstantinopoulos PA, Luo W, Liu JF, Gulhan DC, Krasner C, Ishizuka JJ, Gockley AA, Buss M, Growdon WB, Crowe H, Campos S, Lindeman NI, Hill S, Stover E, Schumer S, Wright AA, Curtis J, Quinn R, Whalen C, Gray KP, Penson RT, Cannistra SA, Fleming GF, Matulonis UA. Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer. J Clin Oncol. 2019 10 20; 37(30):2786-2794. PMID: 31461377.
    Citations:    
  6. Bouberhan S, Shea M, Cannistra SA. Reply to R.J. Buckanovich et al. J Clin Oncol. 2019 10 10; 37(29):2708-2709. PMID: 31449467.
    Citations:    
  7. Bouberhan S, Pujade-Lauraine E, Cannistra SA. Advances in the Management of Platinum-Sensitive Relapsed Ovarian Cancer. J Clin Oncol. 2019 09 20; 37(27):2424-2436. PMID: 31403861.
    Citations:    
  8. Cannistra SA, Pujade-Lauraine E. Progress and Promise in Treating Gynecologic Cancers. J Clin Oncol. 2019 09 20; 37(27):2383-2385. PMID: 31403869.
    Citations:    
  9. Bouberhan S, Shea M, Cannistra SA. Advanced Epithelial Ovarian Cancer: Do More Options Mean Greater Benefits? J Clin Oncol. 2019 06 01; 37(16):1359-1364. PMID: 31002579.
    Citations:    
  10. Bouberhan S, Shea M, Cannistra SA. Maintenance PARP inhibitor therapy: is maintaining quality of life enough? Lancet Oncol. 2018 10; 19(10):e504. PMID: 30303117.
    Citations:    Fields:    
  11. Cannistra SA. In the Pursuit of Excellence: Reflections From the Editor-in-Chief of Journal of Clinical Oncology. J Clin Oncol. 2016 Oct 20; 34(30):3589-3590. PMID: 27621398.
    Citations:    Fields:    
  12. Zerillo JA, Cannistra SA, Totte C. Raising the safety bar: The hematology/oncology patient safety committee. J Clin Oncol. 2014 Oct 20; 32(30_suppl):144. PMID: 28141286.
    Citations:    
  13. Liu JF, Cannistra SA. Emerging role for bevacizumab in combination with chemotherapy for patients with platinum-resistant ovarian cancer. J Clin Oncol. 2014 May 01; 32(13):1287-9. PMID: 24637996.
    Citations: 4     Fields:    Translation:Humans
  14. Goodwin PJ, Ballman KV, Small EJ, Levine M, Cannistra SA. Reply to C.M. Booth et al. J Clin Oncol. 2013 Sep 10; 31(26):3300. PMID: 23943837.
    Citations:    Fields:    Translation:Humans
  15. Goodwin PJ, Ballman KV, Small EJ, Cannistra SA. Evaluation of treatment benefit in Journal of Clinical Oncology. J Clin Oncol. 2013 Mar 20; 31(9):1123-4. PMID: 23358984.
    Citations: 5     Fields:    Translation:Humans
  16. Konstantinopoulos PA, Berlin ST, Campos SM, Matulonis UA, Cannistra SA. Bevacizumab rechallenge after first line maintenance bevacizumab. Gynecol Oncol. 2012 May; 125(2):510-1. PMID: 22366591.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  17. Konstantinopoulos PA, Cannistra SA. Comparing poly (ADP-ribose) polymerase inhibitors with standard chemotherapy in BRCA-mutated, recurrent ovarian cancer: lessons learned from a negative trial. J Clin Oncol. 2012 Feb 01; 30(4):347-50. PMID: 22203759.
    Citations: 7     Fields:    Translation:Humans
  18. Janco JM, Hacker MR, Konstantinopoulos PA, Cannistra SA, Awtrey CS. Laparoscopic intraperitoneal port placement for optimally cytoreduced advanced ovarian cancer. J Minim Invasive Gynecol. 2011 Sep-Oct; 18(5):629-33. PMID: 21803662.
    Citations:    Fields:    Translation:Humans
  19. Konstantinopoulos PA, Spentzos D, Fountzilas E, Francoeur N, Sanisetty S, Grammatikos AP, Hecht JL, Cannistra SA. Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer. Cancer Res. 2011 Aug 01; 71(15):5081-9. PMID: 21676886.
    Citations: 65     Fields:    Translation:HumansCells
  20. Cannistra SA. New initiatives at Journal of Clinical Oncology. J Clin Oncol. 2011 Jul 01; 29(19):2609-10. PMID: 21646608.
    Citations:    Fields:    Translation:Humans
  21. Konstantinopoulos PA, Cannistra SA, Fountzilas H, Culhane A, Pillay K, Rueda B, Cramer D, Seiden M, Birrer M, Coukos G, Zhang L, Quackenbush J, Spentzos D. Integrated analysis of multiple microarray datasets identifies a reproducible survival predictor in ovarian cancer. PLoS One. 2011 Mar 29; 6(3):e18202. PMID: 21479231.
    Citations: 13     Fields:    Translation:HumansCells
  22. Verweij J, Disis ML, Cannistra SA. Phase I studies of drug combinations. J Clin Oncol. 2010 Oct 20; 28(30):4545-6. PMID: 20855831.
    Citations: 5     Fields:    Translation:Humans
  23. Konstantinopoulos PA, Spentzos D, Karlan BY, Taniguchi T, Fountzilas E, Francoeur N, Levine DA, Cannistra SA. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol. 2010 Aug 01; 28(22):3555-61. PMID: 20547991.
    Citations: 127     Fields:    Translation:HumansCells
  24. Cannistra SA. Evaluating new regimens in recurrent ovarian cancer: how much evidence is good enough? J Clin Oncol. 2010 Jul 01; 28(19):3101-3. PMID: 20516442.
    Citations: 12     Fields:    Translation:Humans
  25. Penson RT, Dizon DS, Cannistra SA, Roche MR, Krasner CN, Berlin ST, Horowitz NS, Disilvestro PA, Matulonis UA, Lee H, King MA, Campos SM. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol. 2010 Jan 01; 28(1):154-9. PMID: 19917843.
    Citations: 29     Fields:    Translation:HumansCTClinical Trials
  26. Matulonis UA, Berlin S, Ivy P, Tyburski K, Krasner C, Zarwan C, Berkenblit A, Campos S, Horowitz N, Cannistra SA, Lee H, Lee J, Roche M, Hill M, Whalen C, Sullivan L, Tran C, Humphreys BD, Penson RT. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol. 2009 Nov 20; 27(33):5601-6. PMID: 19826113.
    Citations: 71     Fields:    Translation:HumansCTClinical Trials
  27. Cannistra SA. Phase II trials in journal of clinical oncology. J Clin Oncol. 2009 Jul 01; 27(19):3073-6. PMID: 19451415.
    Citations: 29     Fields:    Translation:Humans
  28. Konstantinopoulos PA, Fountzilas E, Pillay K, Zerbini LF, Libermann TA, Cannistra SA, Spentzos D. Carboplatin-induced gene expression changes in vitro are prognostic of survival in epithelial ovarian cancer. BMC Med Genomics. 2008 Nov 28; 1:59. PMID: 19038057.
    Citations: 17     Fields:    
  29. Cannistra SA. Challenges and pitfalls of combining targeted agents in phase I studies. J Clin Oncol. 2008 Aug 01; 26(22):3665-7. PMID: 18669449.
    Citations: 14     Fields:    Translation:Humans
  30. Konstantinopoulos PA, Spentzos D, Cannistra SA. Gene-expression profiling in epithelial ovarian cancer. Nat Clin Pract Oncol. 2008 Oct; 5(10):577-87. PMID: 18648354.
    Citations: 44     Fields:    Translation:Humans
  31. Cannistra SA. BRCA-1 in sporadic epithelial ovarian cancer: lessons learned from the genetics of hereditary disease. Clin Cancer Res. 2007 Dec 15; 13(24):7225-7. PMID: 18094398.
    Citations: 1     Fields:    Translation:Humans
  32. Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, Douglas J, Burger RA, Armstrong D, Wenham R, McGuire W. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007 Nov 20; 25(33):5180-6. PMID: 18024865.
    Citations: 200     Fields:    Translation:HumansCTClinical Trials
  33. Spentzos D, Cannistra SA, Grall F, Levine DA, Pillay K, Libermann TA, Mantzoros CS. IGF axis gene expression patterns are prognostic of survival in epithelial ovarian cancer. Endocr Relat Cancer. 2007 Sep; 14(3):781-90. PMID: 17914107.
    Citations: 19     Fields:    Translation:HumansCells
  34. Comander AH, Cannistra SA. A feasibility study of low-dose, prolonged oral topotecan in patients with advanced ovarian, fallopian tube, or primary peritoneal serous cancer who have attained a complete clinical response following platinum-based chemotherapy. Int J Gynecol Cancer. 2008 Jan-Feb; 18(1):51-8. PMID: 17506844.
    Citations:    Fields:    Translation:Humans
  35. Cannistra SA. Performance of biopsies in clinical research. J Clin Oncol. 2007 Apr 10; 25(11):1454-5. PMID: 17416872.
    Citations: 9     Fields:    Translation:Humans
  36. Cannistra SA. Gynecologic oncology or medical oncology: what's in a name? J Clin Oncol. 2007 Apr 01; 25(10):1157-9. PMID: 17401003.
    Citations:    Fields:    Translation:Humans
  37. Cannistra SA, Matulonis U, Penson R, Wenham R, Armstrong D, Burger RA, Mackey H, Douglas J, Hambleton J, McGuire W. Bevacizumab in patients with advanced platinum-resistant ovarian cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):5006. PMID: 27952183.
    Citations:    
  38. Penson RT, Cannistra SA, Seiden MV, Krasner CN, Matulonis UA, Horowitz NS, Berlin S, Dizon DS, Lee H, Campos SM. Phase II study of carboplatin, paclitaxel and bevacizumab as first line chemotherapy and consolidation for advanced müllerian tumors. J Clin Oncol. 2006 Jun 20; 24(18_suppl):5020. PMID: 27952190.
    Citations:    
  39. Cannistra SA. Intraperitoneal chemotherapy comes of age. N Engl J Med. 2006 Jan 05; 354(1):77-9. PMID: 16394306.
    Citations: 7     Fields:    Translation:Humans
  40. Spentzos D, Levine DA, Kolia S, Otu H, Boyd J, Libermann TA, Cannistra SA. Unique gene expression profile based on pathologic response in epithelial ovarian cancer. J Clin Oncol. 2005 Nov 01; 23(31):7911-8. PMID: 16204010.
    Citations: 39     Fields:    Translation:Humans
  41. Berkenblit A, Cannistra SA. Advances in the management of epithelial ovarian cancer. J Reprod Med. 2005 Jun; 50(6):426-38. PMID: 16050567.
    Citations: 28     Fields:    Translation:Humans
  42. Cannistra SA. Cancer of the ovary. N Engl J Med. 2004 Dec 09; 351(24):2519-29. PMID: 15590954.
    Citations: 456     Fields:    Translation:Humans
  43. Berkenblit A, Seiden MV, Matulonis UA, Penson RT, Krasner CN, Roche M, Mezzetti L, Atkinson T, Cannistra SA. A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer. Gynecol Oncol. 2004 Dec; 95(3):624-31. PMID: 15581974.
    Citations: 11     Fields:    Translation:HumansCTClinical Trials
  44. Spentzos D, Levine DA, Ramoni MF, Joseph M, Gu X, Boyd J, Libermann TA, Cannistra SA. Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol. 2004 Dec 01; 22(23):4700-10. PMID: 15505275.
    Citations: 70     Fields:    Translation:Humans
  45. Cannistra SA. The ethics of early stopping rules: who is protecting whom? J Clin Oncol. 2004 May 01; 22(9):1542-5. PMID: 15117977.
    Citations: 9     Fields:    Translation:Humans
  46. Berkenblit A, Tung N, Kim Y, Feyler H, Niloff J, Berghe KV, Cannistra SA. Phase I trial of docetaxel, carboplatin, and gemcitabine as first-line therapy for patients with high-risk epithelial tumors of müllerian origin. Gynecol Oncol. 2003 Jun; 89(3):486-93. PMID: 12798716.
    Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
  47. Cannistra SA, Bast RC, Berek JS, Bookman MA, Crum CP, DePriest PD, Garber JE, Koh WJ, Markman M, McGuire WP, Rose PG, Rowinsky EK, Rustin GJ, Skates SJ, Vasey PA, King L. Progress in the management of gynecologic cancer: consensus summary statement. J Clin Oncol. 2003 May 15; 21(10 Suppl):129s-132s. PMID: 12743127.
    Citations: 11     Fields:    Translation:HumansPHPublic Health
  48. Schumer ST, Cannistra SA. Granulosa cell tumor of the ovary. J Clin Oncol. 2003 Mar 15; 21(6):1180-9. PMID: 12637488.
    Citations: 82     Fields:    Translation:HumansPHPublic Health
  49. Cannistra SA. Is there a "best" choice of second-line agent in the treatment of recurrent, potentially platinum-sensitive ovarian cancer? J Clin Oncol. 2002 Mar 01; 20(5):1158-60. PMID: 11870154.
    Citations: 17     Fields:    Translation:Humans
  50. Raffel GD, Gravallese EM, Schwab P, Joseph JT, Cannistra SA. Diagnostic dilemmas in oncology: case 2. Dermatomyositis and ovarian cancer. J Clin Oncol. 2001 Dec 01; 19(23):4341-3. PMID: 11731518.
    Citations: 2     Fields:    Translation:Humans
  51. Smith WM, Zhou XP, Kurose K, Gao X, Latif F, Kroll T, Sugano K, Cannistra SA, Clinton SK, Maher ER, Prior TW, Eng C. Opposite association of two PPARG variants with cancer: overrepresentation of H449H in endometrial carcinoma cases and underrepresentation of P12A in renal cell carcinoma cases. Hum Genet. 2001 Aug; 109(2):146-51. PMID: 11511919.
    Citations: 16     Fields:    Translation:Humans
  52. Kurose K, Zhou XP, Araki T, Cannistra SA, Maher ER, Eng C. Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am J Pathol. 2001 Jun; 158(6):2097-106. PMID: 11395387.
    Citations: 54     Fields:    Translation:HumansCells
  53. Cannistra SA. When is a "prognostic factor" really prognostic? J Clin Oncol. 2000 Nov 15; 18(22):3745-7. PMID: 11078486.
    Citations: 2     Fields:    Translation:Humans
  54. Gong J, Nikrui N, Chen D, Koido S, Wu Z, Tanaka Y, Cannistra S, Avigan D, Kufe D. Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. J Immunol. 2000 Aug 01; 165(3):1705-11. PMID: 10903782.
    Citations: 39     Fields:    Translation:HumansCells
  55. Tung N, Berkowitz R, Matulonis U, Quartulli M, Seiden M, Kim Y, Niloff J, Cannistra SA. Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer. Gynecol Oncol. 2000 May; 77(2):271-7. PMID: 10785477.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  56. Strobel T, Cannistra SA. Beta1-integrins partly mediate binding of ovarian cancer cells to peritoneal mesothelium in vitro. Gynecol Oncol. 1999 Jun; 73(3):362-7. PMID: 10366461.
    Citations: 58     Fields:    Translation:HumansCells
  57. Tai YT, Strobel T, Kufe D, Cannistra SA. In vivo cytotoxicity of ovarian cancer cells through tumor-selective expression of the BAX gene. Cancer Res. 1999 May 01; 59(9):2121-6. PMID: 10232598.
    Citations: 7     Fields:    Translation:HumansAnimalsCells
  58. Cannistra SA. Back to the future: multiagent chemotherapy in ovarian cancer revisited. J Clin Oncol. 1999 Mar; 17(3):741-3. PMID: 10071260.
    Citations: 2     Fields:    Translation:Humans
  59. Strobel T, Tai YT, Korsmeyer S, Cannistra SA. BAD partly reverses paclitaxel resistance in human ovarian cancer cells. Oncogene. 1998 Nov 12; 17(19):2419-27. PMID: 9824152.
    Citations: 4     Fields:    Translation:HumansAnimalsCells
  60. Strobel T, Kraeft SK, Chen LB, Cannistra SA. BAX expression is associated with enhanced intracellular accumulation of paclitaxel: a novel role for BAX during chemotherapy-induced cell death. Cancer Res. 1998 Nov 01; 58(21):4776-81. PMID: 9809975.
    Citations: 6     Fields:    Translation:HumansCells
  61. Fink D, Nebel S, Norris PS, Baergen RN, Wilczynski SP, Costa MJ, Haas M, Cannistra SA, Howell SB. Enrichment for DNA mismatch repair-deficient cells during treatment with cisplatin. Int J Cancer. 1998 Aug 31; 77(5):741-6. PMID: 9688308.
    Citations: 9     Fields:    Translation:HumansAnimalsCells
  62. Tai YT, Lee S, Niloff E, Weisman C, Strobel T, Cannistra SA. BAX protein expression and clinical outcome in epithelial ovarian cancer. J Clin Oncol. 1998 Aug; 16(8):2583-90. PMID: 9704707.
    Citations: 24     Fields:    Translation:Humans
  63. Cannistra SA. "Cancer defeated": not if, but when--introducing the Biology of Neoplasia series. J Clin Oncol. 1997 Nov; 15(11):3297-8. PMID: 9363857.
    Citations:    Fields:    Translation:Humans
  64. Strobel T, Swanson L, Korsmeyer S, Cannistra SA. Radiation-induced apoptosis is not enhanced by expression of either p53 or BAX in SW626 ovarian cancer cells. Oncogene. 1997 Jun 12; 14(23):2753-8. PMID: 9190890.
    Citations: 5     Fields:    Translation:HumansCells
  65. Cannistra SA. BRCA1 mutations and survival in women with ovarian cancer. N Engl J Med. 1997 Apr 24; 336(17):1254; author reply 1256-7. PMID: 9121519.
    Citations: 2     Fields:    Translation:Humans
  66. Strobel T, Swanson L, Cannistra SA. In vivo inhibition of CD44 limits intra-abdominal spread of a human ovarian cancer xenograft in nude mice: a novel role for CD44 in the process of peritoneal implantation. Cancer Res. 1997 Apr 01; 57(7):1228-32. PMID: 9102203.
    Citations: 47     Fields:    Translation:HumansAnimalsCells
  67. Strobel T, Swanson L, Korsmeyer S, Cannistra SA. BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway. Proc Natl Acad Sci U S A. 1996 Nov 26; 93(24):14094-9. PMID: 8943066.
    Citations: 29     Fields:    Translation:HumansAnimalsCells
  68. Ottensmeier C, Swanson L, Strobel T, Druker B, Niloff J, Cannistra SA. Absence of constitutive EGF receptor activation in ovarian cancer cell lines. Br J Cancer. 1996 Aug; 74(3):446-52. PMID: 8695362.
    Citations: 2     Fields:    Translation:HumansCells
  69. Cannistra SA, Niloff JM. Cancer of the uterine cervix. N Engl J Med. 1996 Apr 18; 334(16):1030-8. PMID: 8598842.
    Citations: 38     Fields:    Translation:HumansCells
  70. Scully R, Ganesan S, Brown M, De Caprio JA, Cannistra SA, Feunteun J, Schnitt S, Livingston DM. Location of BRCA1 in human breast and ovarian cancer cells. Science. 1996 Apr 05; 272(5258):123-6. PMID: 8600523.
    Citations: 47     Fields:    Translation:HumansCells
  71. Abu-Jawdeh GM, Jacobs TW, Niloff J, Cannistra SA. Estrogen receptor expression is a common feature of ovarian borderline tumors. Gynecol Oncol. 1996 Feb; 60(2):301-7. PMID: 8631556.
    Citations: 9     Fields:    Translation:Humans
  72. Cannistra SA, Abu-Jawdeh G, Niloff J, Strobel T, Swanson L, Andersen J, Ottensmeier C. CD44 variant expression is a common feature of epithelial ovarian cancer: lack of association with standard prognostic factors. J Clin Oncol. 1995 Aug; 13(8):1912-21. PMID: 7543560.
    Citations: 24     Fields:    Translation:HumansCells
  73. Cannistra SA, Ottensmeier C, Niloff J, Orta B, DiCarlo J. Expression and function of beta 1 and alpha v beta 3 integrins in ovarian cancer. Gynecol Oncol. 1995 Aug; 58(2):216-25. PMID: 7542622.
    Citations: 39     Fields:    Translation:HumansCells
  74. Cannistra SA. Interval cytoreduction in ovarian cancer. N Engl J Med. 1995 Jul 27; 333(4):255. PMID: 7791845.
    Citations:    Fields:    Translation:Humans
  75. Cannistra SA, DeFranzo B, Niloff J, Ottensmeir C. Functional heterogeneity of CD44 molecules in ovarian cancer cell lines. Clin Cancer Res. 1995 Mar; 1(3):333-42. PMID: 9815989.
    Citations: 10     Fields:    Translation:HumansCells
  76. Cannistra SA, Ottensmeier C, Tidy J, DeFranzo B. Vascular cell adhesion molecule-1 expressed by peritoneal mesothelium partly mediates the binding of activated human T lymphocytes. Exp Hematol. 1994 Sep; 22(10):996-1002. PMID: 7522188.
    Citations: 9     Fields:    Translation:HumansCells
  77. Cannistra SA. Paclitaxel in ovarian cancer: how can we make it better? J Clin Oncol. 1994 Sep; 12(9):1743-4. PMID: 7916037.
    Citations:    Fields:    Translation:Humans
  78. Cannistra SA. Cancer of the ovary. N Engl J Med. 1993 Nov 18; 329(21):1550-9. PMID: 8155119.
    Citations: 63     Fields:    Translation:Humans
  79. Cannistra SA. 111In-CYT-103 immunoscintigraphy in ovarian cancer. Gynecol Oncol. 1993 Nov; 51(2):292-4. PMID: 8276314.
    Citations:    Fields:    Translation:Humans
  80. Cannistra SA, Kansas GS, Niloff J, DeFranzo B, Kim Y, Ottensmeier C. Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partly mediated by CD44H. Cancer Res. 1993 Aug 15; 53(16):3830-8. PMID: 8339295.
    Citations: 70     Fields:    Translation:HumansCells
  81. Tepler I, Cannistra SA, Frei E, Gonin R, Anderson KC, Demetri G, Niloff J, Goodman H, Muntz H, Muto M, et al. Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy. J Clin Oncol. 1993 Aug; 11(8):1583-91. PMID: 8101563.
    Citations: 4     Fields:    Translation:Humans
  82. Robertson MJ, Tantravahi R, Griffin JD, Canellos GP, Cannistra SA. Hematologic remission and cytogenetic improvement after treatment of stable-phase chronic myelogenous leukemia with continuous infusion of low-dose cytarabine. Am J Hematol. 1993 Jun; 43(2):95-102. PMID: 8342558.
    Citations: 1     Fields:    Translation:HumansCells
  83. Uchiyama H, Barut BA, Chauhan D, Cannistra SA, Anderson KC. Characterization of adhesion molecules on human myeloma cell lines. Blood. 1992 Nov 01; 80(9):2306-14. PMID: 1421401.
    Citations: 23     Fields:    Translation:HumansCells
  84. Koenigsmann M, Griffin JD, DiCarlo J, Cannistra SA. Myeloid and erythroid progenitor cells from normal bone marrow adhere to collagen type I. Blood. 1992 Feb 01; 79(3):657-65. PMID: 1370640.
    Citations: 9     Fields:    Translation:HumansCells
  85. Kanakura Y, Cannistra SA, Brown CB, Nakamura M, Seelig GF, Prosise WW, Hawkins JC, Kaushansky K, Griffin JD. Identification of functionally distinct domains of human granulocyte-macrophage colony-stimulating factor using monoclonal antibodies. Blood. 1991 Mar 01; 77(5):1033-43. PMID: 1704802.
    Citations: 6     Fields:    Translation:HumansAnimalsCells
  86. Cannistra SA, DiCarlo J, Groshek P, Kanakura Y, Berg D, Mayer RJ, Griffin JD. Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia. Leukemia. 1991 Mar; 5(3):230-8. PMID: 1826536.
    Citations: 4     Fields:    Translation:HumansCellsCTClinical Trials
  87. Cannistra SA. Why should the clonogenic cell assay be prognostically important in ovarian cancer? J Clin Oncol. 1991 Mar; 9(3):368-70. PMID: 1999705.
    Citations:    Fields:    Translation:Humans
  88. Cannistra SA. Growth regulation of malignant clonogenic cells in acute myeloid leukemia. Curr Opin Oncol. 1991 Feb; 3(1):4-12. PMID: 1828375.
    Citations:    Fields:    Translation:HumansCells
  89. Kanakura Y, Druker B, DiCarlo J, Cannistra SA, Griffin JD. Phorbol 12-myristate 13-acetate inhibits granulocyte-macrophage colony stimulating factor-induced protein tyrosine phosphorylation in a human factor-dependent hematopoietic cell line. J Biol Chem. 1991 Jan 05; 266(1):490-5. PMID: 1845978.
    Citations: 10     Fields:    Translation:HumansCells
  90. Kanakura Y, Druker B, Cannistra SA, Furukawa Y, Torimoto Y, Griffin JD. Signal transduction of the human granulocyte-macrophage colony-stimulating factor and interleukin-3 receptors involves tyrosine phosphorylation of a common set of cytoplasmic proteins. Blood. 1990 Aug 15; 76(4):706-15. PMID: 2166606.
    Citations: 48     Fields:    Translation:HumansCells
  91. Cannistra SA, Koenigsmann M, DiCarlo J, Groshek P, Griffin JD. Differentiation-associated expression of two functionally distinct classes of granulocyte-macrophage colony-stimulating factor receptors by human myeloid cells. J Biol Chem. 1990 Jul 25; 265(21):12656-63. PMID: 2165070.
    Citations: 5     Fields:    Translation:HumansCells
  92. Dadmarz R, Rabinowe SN, Cannistra SA, Andersen JW, Freedman AS, Nadler LM. Association between clonogenic cell growth and clinical risk group in B-cell chronic lymphocytic leukemia. Blood. 1990 Jul 01; 76(1):142-9. PMID: 2194588.
    Citations: 2     Fields:    Translation:HumansCells
  93. Cannistra SA. Chronic myelogenous leukemia as a model for the genetic basis of cancer. Hematol Oncol Clin North Am. 1990 Apr; 4(2):337-57. PMID: 2182595.
    Citations:    Fields:    Translation:HumansCells
  94. Roy DC, Felix M, Cannady WG, Cannistra S, Ritz J. Comparative activities of rabbit complements of different ages using an in-vitro marrow purging model. Leuk Res. 1990; 14(5):407-16. PMID: 2345466.
    Citations: 3     Fields:    Translation:HumansAnimalsCells
  95. Griffin JD, Cannistra SA, Sullivan R, Demetri GD, Ernst TJ, Kanakura Y. The biology of GM-CSF: regulation of production and interaction with its receptor. Int J Cell Cloning. 1990 Jan; 8 Suppl 1:35-44; discussion 44-5. PMID: 2157777.
    Citations: 11     Fields:    Translation:HumansAnimalsCells
  96. Cannistra SA, Groshek P, Garlick R, Miller J, Griffin JD. Regulation of surface expression of the granulocyte/macrophage colony-stimulating factor receptor in normal human myeloid cells. Proc Natl Acad Sci U S A. 1990 Jan; 87(1):93-7. PMID: 2153304.
    Citations: 8     Fields:    Translation:HumansCells
  97. Griffin JD, Demetri GD, Kanakura Y, Cannistra SA, Ernst TJ. Cellular interaction regulating the production of colony-stimulating factors. Prog Clin Biol Res. 1990; 338:129-41. PMID: 2189136.
    Citations:    Fields:    Translation:HumansAnimalsCells
  98. Cannistra SA, Groshek P, Griffin JD. Granulocyte-macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myeloid leukemia. Leukemia. 1989 May; 3(5):328-34. PMID: 2654494.
    Citations: 11     Fields:    Translation:HumansCells
  99. Herrmann F, Cannistra SA, Lindemann A, Blohm D, Rambaldi A, Mertelsmann RH, Griffin JD. Functional consequences of monocyte IL-2 receptor expression. Induction of IL-1 beta secretion by IFN gamma and IL-2. J Immunol. 1989 Jan 01; 142(1):139-43. PMID: 2491871.
    Citations: 9     Fields:    Translation:HumansCells
  100. Herrmann F, Lindemann A, Cannistra SA, Brach M, Oster W, Griffin JD, Mertelsmann R. Monocyte interleukin-1 secretion is regulated by the sequential action of gamma-interferon and interleukin-2 involving monocyte surface expression of interleukin-2 receptors. Haematol Blood Transfus. 1989; 32:299-315. PMID: 2516496.
    Citations:    Fields:    Translation:HumansCells
  101. Cannistra SA, Groshek P, Griffin JD. Monocytes enhance gamma-interferon-induced inhibition of myeloid progenitor cell growth through secretion of tumor necrosis factor. Exp Hematol. 1988 Nov; 16(10):865-70. PMID: 3139436.
    Citations: 2     Fields:    Translation:HumansCells
  102. Antman KS, Griffin JD, Elias A, Socinski MA, Ryan L, Cannistra SA, Oette D, Whitley M, Frei E, Schnipper LE. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med. 1988 Sep 08; 319(10):593-8. PMID: 3045544.
    Citations: 64     Fields:    Translation:Humans
  103. Socinski MA, Cannistra SA, Sullivan R, Elias A, Antman K, Schnipper L, Griffin JD. Granulocyte-macrophage colony-stimulating factor induces the expression of the CD11b surface adhesion molecule on human granulocytes in vivo. Blood. 1988 Aug; 72(2):691-7. PMID: 3042045.
    Citations: 21     Fields:    Translation:HumansCells
  104. Cannistra SA, Griffin JD. Regulation of the production and function of granulocytes and monocytes. Semin Hematol. 1988 Jul; 25(3):173-88. PMID: 3043672.
    Citations: 25     Fields:    Translation:HumansCells
  105. Young DC, Demetri GD, Ernst TJ, Cannistra SA, Griffin JD. In vitro expression of colony-stimulating factor genes by human acute myeloblastic leukemia cells. Exp Hematol. 1988 Jun; 16(5):378-82. PMID: 2453374.
    Citations: 8     Fields:    Translation:HumansCells
  106. Socinski MA, Cannistra SA, Elias A, Antman KH, Schnipper L, Griffin JD. Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet. 1988 May 28; 1(8596):1194-8. PMID: 2897009.
    Citations: 45     Fields:    Translation:HumansCells
  107. Cannistra SA, Vellenga E, Groshek P, Rambaldi A, Griffin JD. Human granulocyte-monocyte colony-stimulating factor and interleukin 3 stimulate monocyte cytotoxicity through a tumor necrosis factor-dependent mechanism. Blood. 1988 Mar; 71(3):672-6. PMID: 3278752.
    Citations: 34     Fields:    Translation:HumansCells
  108. Griffin JD, Rambaldi A, Vellenga E, Young DC, Ostapovicz D, Cannistra SA. Secretion of interleukin-1 by acute myeloblastic leukemia cells in vitro induces endothelial cells to secrete colony stimulating factors. Blood. 1987 Oct; 70(4):1218-21. PMID: 3498521.
    Citations: 24     Fields:    Translation:HumansCells
  109. Cannistra SA, Rambaldi A, Spriggs DR, Herrmann F, Kufe D, Griffin JD. Human granulocyte-macrophage colony-stimulating factor induces expression of the tumor necrosis factor gene by the U937 cell line and by normal human monocytes. J Clin Invest. 1987 Jun; 79(6):1720-8. PMID: 3294900.
    Citations: 27     Fields:    Translation:HumansCells
  110. Rambaldi A, Young DC, Herrmann F, Cannistra SA, Griffin JD. Interferon-gamma induces expression of the interleukin 2 receptor gene in human monocytes. Eur J Immunol. 1987 Jan; 17(1):153-6. PMID: 3102253.
    Citations: 12     Fields:    Translation:HumansCells
  111. Herrmann F, Cannistra SA, Griffin JD. T cell-monocyte interactions in the production of humoral factors regulating human granulopoiesis in vitro. J Immunol. 1986 Apr 15; 136(8):2856-61. PMID: 3082974.
    Citations: 8     Fields:    Translation:HumansCells
  112. Cannistra SA, Herrmann F, Davis R, Nichols K, Griffin JD. Relationship between HLA-DR expression by normal myeloid progenitor cells and inhibition of colony growth by prostaglandin E. Implications for prostaglandin E resistance in chronic myeloid leukemia. J Clin Invest. 1986 Jan; 77(1):13-20. PMID: 3455931.
    Citations: 4     Fields:    Translation:HumansCells
  113. Griffin JD, Sabbath KD, Herrmann F, Larcom P, Nichols K, Kornacki M, Levine H, Cannistra SA. Differential expression of HLA-DR antigens in subsets of human CFU-GM. Blood. 1985 Oct; 66(4):788-95. PMID: 3929858.
    Citations: 4     Fields:    Translation:HumansCells
  114. Herrmann F, Cannistra SA, Levine H, Griffin JD. Expression of interleukin 2 receptors and binding of interleukin 2 by gamma interferon-induced human leukemic and normal monocytic cells. J Exp Med. 1985 Sep 01; 162(3):1111-6. PMID: 3928803.
    Citations: 60     Fields:    Translation:HumansCells
  115. Cannistra SA, Daley JF, Larcom P, Griffin JD. Expression of Ia antigens on myeloid progenitor cells in chronic myeloid leukemia: direct analysis using partially purified colony-forming cells. Blood. 1985 Feb; 65(2):414-22. PMID: 3855362.
    Citations: 3     Fields:    Translation:HumansCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Cannistra's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (453)
Explore
_
Co-Authors (52)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.